ADMA icon

ADMA Biologics

19.84 USD
-0.42
2.07%
At close Mar 31, 4:00 PM EDT
After hours
19.83
-0.01
0.05%
1 day
-2.07%
5 days
-1.98%
1 month
21.05%
3 months
15.69%
6 months
-0.75%
Year to date
10.41%
1 year
203.36%
5 years
588.89%
10 years
102.45%
 

About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Employees: 685

0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

179% more call options, than puts

Call options by funds: $43.8M | Put options by funds: $15.7M

32% more first-time investments, than exits

New positions opened: 75 | Existing positions closed: 57

22% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 102

4% more funds holding

Funds holding: 305 [Q3] → 318 (+13) [Q4]

3.35% less ownership

Funds ownership: 89.61% [Q3] → 86.26% (-3.35%) [Q4]

16% less capital invested

Capital invested by funds: $4.17B [Q3] → $3.5B (-$668M) [Q4]

29% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$25
26%
upside
Avg. target
$25
26%
upside
High target
$25
26%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Kristen Kluska
31% 1-year accuracy
34 / 108 met price target
26%upside
$25
Overweight
Reiterated
4 Mar 2025

Financial journalist opinion

Based on 18 articles about ADMA published over the past 30 days

Neutral
Zacks Investment Research
19 hours ago
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
Positive
Zacks Investment Research
5 days ago
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
ADMA Biologics Inc (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
Positive
Zacks Investment Research
1 week ago
Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock
Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock
Positive
Seeking Alpha
1 week ago
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% year-over-year revenue increase, with strong gross profit margins and minimal R&D expenses, highlighting ADMA's efficient operations. Financial health is solid with $103.147 million in cash and manageable liabilities, supporting long-term growth and investment potential.
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
Positive
Investors Business Daily
1 week ago
ADMA Stock Builds A Base As Profits Continue To Soar
This biopharmaceutical firm specializes in treatments to prevent and treat infectious diseases. The post ADMA Stock Builds A Base As Profits Continue To Soar appeared first on Investor's Business Daily.
ADMA Stock Builds A Base As Profits Continue To Soar
Positive
Zacks Investment Research
1 week ago
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?
Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?
Positive
Zacks Investment Research
1 week ago
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Positive
Zacks Investment Research
2 weeks ago
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
In the most recent trading session, Adma Biologics (ADMA) closed at $18.67, indicating a +1.3% shift from the previous trading day.
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
Positive
Zacks Investment Research
2 weeks ago
Will ADMA Biologics Stock Continue Its Momentum in 2025?
ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.
Will ADMA Biologics Stock Continue Its Momentum in 2025?
Charts implemented using Lightweight Charts™